Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_6884



Chemical Information
Antiviral agent IDDrugRepV_6884
Antiviral agent name4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide
IUPAC Name4-[5-(2-methylphenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]benzene-1-sulfonamide PubChem
SMILES (canonical)[H]N([H])S(=O)(=O)C1=CC=C(C=C1)N1N=C(CC1C1=CC=CC=C1C)C1=CC=C(OC2=CC=CC=C2)C=C1 PubChem
Molecular FormulaC28H25N3O3S PubChem
Molecular Weight (g/mol)483.59 PubChem
InChlInChI=1/C28H25N3O3S/c1-20-7-5-6-10-26(20)28-19-27(30-31(28)22-13-17-25(18-14-22)35(29,32)33)21-11-15-24(16-12-21)34-23-8-3-2-4-9-23/h2-18,28H,19H2,1H3,(H2,29,32,33) PubChem
Structural Information
  
Clinical Information
Biological Information
Secondary Indication Human immunodeficiency virus (HIV) 1 NAWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)In-vitro
Secondary Indication (Model system) [cell lines/ animal models]BHK-21
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)0.01 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Drug concentration)13.0 ± 0.6 μM
Secondary Indication (Cell based assay)MTT assay
Secondary Indication (Change)Decrease
Secondary Indication (Type of Inhibition) EC50 [ 50 % ]
Secondary Indication (Cytotoxicity)7 μM
ReferenceFioravanti R, Desideri N, Carta A, Atzori EM, Delogu I, Collu G, Loddo R..Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation..Eur J Med Chem. 2017 Dec 1;141:15-25. doi: 10.1016/j.ejmech.2017.09.060. Epub 2017 Sep 28. PMID:29028528 PubMed
Comment6-Azauridine, ribavirin, 2'-C-methyl-guanosin (NM108), efavirenz (EFV), pleconaril, acyclovir (ACG), and mycophenolic acid (M5255) were employed as reference inhibitors.